London stocks ended Tuesday in mixed territory, amid subdued trading in the absence of significant economic data, leaving ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. | GSK has secured the first regulatory approval for Blenrep since the ...

The London-based pharmaceutical company said Blenrep, or belantamab mafodotin, was approved for the treatment of adult patients with multiple myeloma in combination with bortezomib plus dexamethasone, ...

She will officially take up the role from June 1, succeeding Sir Norman Lamb, who retired in March after five years of dedicated service.

UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports ...

Arexvy, already approved in over 60 countries, was supported by trial data showing safety and immune response in the 50–59 age group. GSK said more than 13 million adults in the US fall into this ...

If the tariff-loving Trump goes ahead with his plans, it will hit AstraZeneca - the most valuable company on the UK stock ...

RSV typically causes cold-like symptoms, but is also a leading cause of pneumonia in toddlers and older adults. An estimated ...

London: British pharmaceutical major GlaxoSmithKline (GSK) has failed to meet the required regulatory and ethical standards ...

In spring 2021, my family sold a big lump of GSK shares. Four years later, we have no regrets. Indeed, with the GSK share price stumbling, we may buy soon.

In spring 2021, my family sold a big lump of GSK shares. Four years later, we have no regrets. Indeed, with the GSK share price stumbling, we may buy soon. The post Were we right to ditch our GSK ...